Goods & Services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Promoting awareness of patient support offerings for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Promoting awareness of patient support offerings for pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Business administration services in the field of healthcare, namely, business administration of reimbursement and medical benefit information for neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions and their treatment; Business administration services in the field of healthcare, namely, business administration of business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, rare neurologic, neuropsychiatric, rare neuropsychiatric, metabolic, rare metabolic, genetic, rare genetic, psychologic, rare psychologic, psychiatric, and rare psychiatric diseases and disorders Printed publications, namely, brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Insurance claims administration; Providing counseling and consulting in the field of healthcare insurance benefits; Providing information about healthcare insurance plans; Providing health insurance information; Providing financial information in the field of medical benefits and reimbursements available for medical expenses related thereto; Providing financial information in the field of insurance benefits and coverage for health care providers and patients in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders Educational services, namely, conducting programs in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders and treatment and patient support options for these conditions Providing on-line non-downloadable software for administering medical benefits and enrolling in benefits patient support program services; Biomedical research services; Industrial research in the field of biotechnology; Scientific research; Scientific and technological services, namely, research and design in the field of biotechnology and biomedicine; Providing scientific research information in the field of biotechnology and biomedicine; Chemical, biochemical, biological and bacteriological research and analysis; Biological research and analysis; Testing of pharmaceuticals; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Pharmaceutical research and development; Pharmaceutical research in the field of medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; Providing medical research information in the field of pharmaceuticals Consultancy in the field of the medical treatment of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Consultancy in the field of the medical diagnosis of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric conditions; Medical information; Providing medical information via a website; Providing personalized healthcare and medical information in the nature of providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders; Providing medical information in the field of neurologic, neuropsychiatric, metabolic, rare, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; Business administrative services for medical referrals Pharmaceutical preparations for the treatment and prevention of neurologic, genetic, psychologic, and psychiatric diseases and disorders Consultancy in the field of the medical treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; Consultancy in the field of the medical diagnosis of neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome; Health care services, namely, providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; Health care services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Abstract

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 211/58 - Nitrogen atoms attached in position 4
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

M4 positive allosteric modulators are disclosed which having a formula or a pharmaceutically acceptable salt or pharmaceutically acceptable salt hydrate or deuterated analog thereof. These compounds may be used for the therapeutic and/or prophylactic treatment of N14mediated diseases or disorders, such as Alzheimer's disease, schizophrenia, psychosis, Parkinson's disease, pain, addiction and Huntington's disease.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• C07D 487/02 - Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups in which the condensed system contains two hetero rings
• C07D 487/04 - Ortho-condensed systems
• A61K 31/33 - Heterocyclic compounds

Abstract

M4 positive allosterie modulators of compound of the formula wherein R1 is a 4- or 5-membered heterocyclic ring, each of which may unsubstituted or substituted by one or more substituents, and which ring contains 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; R2 is a C1-C6 alkyl group; A is a 4- or 5-membered heterocyclic ring, each of which may be unsubstituted or substituted by one or more substituents, and which ring contains 1, 2, or 3 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur; R3 is a hydrogen atom or a C1-C6 alkyl group; and Ar is a 5-10 membered heterocyclic, aromatic or heteroaromatic monocyclic or bicyclic ring.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/505 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/33 - Heterocyclic compounds

Goods & Services

Pharmaceutical preparations for the treatment of Prader-Willi syndrome (PWS) and related disorders; Pharmaceutical preparations for the treatment of neurodevelopmental and metabolic disorders

Goods & Services

Pharmaceutical preparations for the treatment of Prader-Willi syndrome (PWS) and related disorders; Pharmaceutical preparations for the treatment of neurodevelopmental and metabolic disorders

Abstract

2A2A.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/24 - Antidepressants
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

IPC Classes  ?

• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Goods & Services

Promoting awareness of patient support offerings for neurodegenerative diseases and disorders and dementia; business administrative services for medical referrals Downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Printed publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment; printed questionnaires on medical issues Educational services, namely, providing educational programs in the nature of classes, seminars, and workshops about neurodegenerative diseases and disorders and dementia and diagnosis, identification, management, treatment, and patient support options for these conditions; multimedia educational services in the nature of recording and production services in the fields of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management distributed via various platforms across multiple forms of transmission media; providing on-line newsletters in the field of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management; online non-downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Testing, inspection, research, and development of diagnostic tests and questionnaires for symptoms of dementia-related psychosis, including hallucinations and delusions associated with dementia-related psychosis Medical consulting with respect to neurodegenerative diseases and disorders and dementia, including dementia-related psychosis and their identification and treatment; providing medical online information for health care providers and patients in the field of neurodegenerative diseases and disorders and dementia; medical informational support services, namely, providing medical information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients and healthcare professionals all related to neurodegenerative diseases and disorders and dementia

Goods & Services

Promoting awareness of patient support offerings for neurodegenerative diseases and disorders and dementia; business administrative services for medical referrals Downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Printed publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment; printed questionnaires on medical issues Educational services, namely, providing educational programs in the nature of classes, seminars, and workshops about neurodegenerative diseases and disorders and dementia and diagnosis, identification, management, treatment, and patient support options for these conditions; multimedia educational services in the nature of recording and production services in the fields of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management distributed via various platforms across multiple forms of transmission media; providing on-line newsletters in the field of neurodegenerative diseases and disorders and dementia, medical informational support services, and medical information regarding disease diagnosis, identification, treatment, and management; online non-downloadable electronic publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurodegenerative diseases and disorders and dementia, patient support, and medical information regarding disease diagnosis, identification, management, and treatment Testing, inspection, research, and development of diagnostic tests and questionnaires for symptoms of dementia-related psychosis, including hallucinations and delusions associated with dementia-related psychosis Medical consulting with respect to neurodegenerative diseases and disorders and dementia, including dementia-related psychosis and their identification and treatment; providing medical online information for health care providers and patients in the field of neurodegenerative diseases and disorders and dementia; medical informational support services, namely, providing medical information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients and healthcare professionals all related to neurodegenerative diseases and disorders and dementia

Goods & Services

(1) Printed publications, namely, pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. (1) Promoting public awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders. (2) Medical referrals (3) Providing education information and instruction to adults, children, and parents of children with neurologic, genetic, psychologic, and psychiatric diseases and disorders; online electronic publishing of pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. (4) Hosting an online community website (5) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders; providing online information for health care providers, caregivers, patients, and families of patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, families of patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; administrative services for medical referrals. Educational services, namely, providing educational information and instruction to adults, children, and parents of children with neurologic, genetic, psychologic, and psychiatric diseases and disorders; publishing of electronic publications and printed matter, namely, pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders; providing online information for health care providers, caregivers, patients, and families of patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, families of patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; Providing an online community website featuring shared communications between community members interested in sharing medical information and experiences in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; administrative services for medical referrals. Educational services, namely, providing educational information and instruction to adults, children, and parents of children with neurologic, genetic, psychologic, and psychiatric diseases and disorders; publishing of electronic publications and printed matter, namely, pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders; providing online information for health care providers, caregivers, patients, and families of patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, families of patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; Hosting an online community website featuring shared communications between community members interested in sharing medical information and experiences in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; administrative services for medical referrals. Educational services, namely, providing educational information and instruction to adults, children, and parents of children with neurologic, genetic, psychologic, and psychiatric diseases and disorders; publishing of electronic publications and printed matter, namely, pamphlets, handbooks, newsletters and brochures about neurologic, genetic, psychologic, and psychiatric diseases and disorders. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders; providing online information for health care providers, caregivers, patients, and families of patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, families of patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; Hosting an online community website featuring shared communications between community members interested in sharing medical information and experiences in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; administrative services for medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Goods & Services

Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support. Promoting awareness of patient support offerings for neurologic, metabolic, rare, and genetic diseases and disorders; promoting awareness of patient support offerings for pain associated with neurologic, metabolic, rare, and genetic diseases and disorders; business administration of reimbursement and medical benefit information for neurologic, metabolic, rare, and genetic conditions and their treatment; business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, metabolic, rare, and genetic conditions; business administrative services for medical referrals. Providing financial information regarding medical benefits and reimbursements available for medical expenses related thereto via a website; insurance services, namely, benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders. Educational services, namely, conducting educational programs in the fields of neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions. Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services. Medical consulting in the fields of neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, metabolic and genetic diseases and disorders.

Goods & Services

Pharmaceuticals preparations for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders.

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders.

Abstract

Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R1, R2, R3, R4, R5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled receptor 88 (GPR88). Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases mediated by GPR88, including Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, Alzheimer's disease, and Attention Deficit Hyperactivity Disorder (ADHD). Disclosed are compounds of the formula (I) and pharmaceutically acceptable salts thereof: (I) wherein Ring A, Ring B, Ring C, R1, R2, R3, R4, R5, L, m, n, and p are as defined herein. The compounds are modulators of G-protein coupled receptor 88 (GPR88). Also disclosed are pharmaceutical compositions comprising the compounds; and the compounds for use in the treatment of diseases mediated by GPR88, including Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, Alzheimer's disease, and Attention Deficit Hyperactivity Disorder (ADHD).

IPC Classes  ?

• C07D 215/08 - Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms with acylated ring nitrogen atom
• C07C 235/22 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
• C07C 235/24 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having at least one of the singly-bound oxygen atoms further bound to a carbon atom of a six-membered aromatic ring, e.g. phenoxyacetamides having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
• C07C 237/40 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
• C07C 237/42 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
• C07C 255/54 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
• C07C 317/32 - SulfonesSulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07D 209/12 - Radicals substituted by oxygen atoms
• C07D 213/56 - Amides
• C07D 213/64 - One oxygen atom attached in position 2 or 6
• C07D 213/74 - Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
• C07D 239/34 - One oxygen atom
• C07D 239/42 - One nitrogen atom
• C07D 265/30 - 1,4-OxazinesHydrogenated 1,4-oxazines not condensed with other rings
• C07D 295/135 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 317/58 - Radicals substituted by nitrogen atoms
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Goods & Services

(1) Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support. (1) Promoting awareness of patient support offerings for neurologic, metabolic, rare, and genetic diseases and disorders; promoting awareness of patient support offerings for pain associated with neurologic, metabolic, rare, and genetic diseases and disorders; business administration of reimbursement and medical benefit information for neurologic, metabolic, rare, and genetic conditions and their treatment; business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, metabolic, rare, and genetic conditions; business administrative services for medical referrals. (2) Providing financial information regarding medical benefits and reimbursements available for medical expenses related thereto via a website; insurance services, namely, benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders. (3) Educational services, namely, conducting educational programs in the fields of neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions. (4) Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services. (5) Medical consulting in the fields of neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, metabolic and genetic diseases and disorders.

Abstract

Behavioral pharmacological data with the compound of formula (I), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that 5HT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07C 59/255 - Tartaric acid
• C07D 211/58 - Nitrogen atoms attached in position 4

Abstract

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more free/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

IPC Classes  ?

• A61K 38/095 - OxytocinsVasopressinsRelated peptides
• A61K 9/08 - Solutions
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Cycloalkylmethoxy- and cycloalkyloxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

IPC Classes  ?

• C07C 233/11 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
• C07D 213/56 - Amides
• C07D 231/12 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Abstract

Alkoxy-substituted N-benzyl-2-phenylacetamide compounds and derivatives are G-protein coupled receptor (GPR) 88 modulators for use in the treatment of a disease mediated by GPR88. Indications include Tourette's Syndrome, Huntington's Disease (HD), Addiction, Parkinson's Disease (PD), Schizophrenia, and Attention Deficit Hyperactivity Disorder (ADHD), choreiform movements, speech delay, learning disabilities, depression, hyperkinetic movement disorders characterised by chorea and/or dystonia, psychosis, cognitive deficits in schizophrenia, affective disorders, bipolar disorder, Alzheimer's disease and basal ganglia disorders.

IPC Classes  ?

• C07D 213/56 - Amides
• C07D 213/65 - One oxygen atom attached in position 3 or 5
• C07D 233/16 - Radicals substituted by nitrogen atoms
• C07D 305/08 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring atoms
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• C07D 333/24 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Goods & Services

Pharmaceutical products and preparations for the treatment of Prader-Willi syndrome (PWS) and related metabolic and neurodevelopmental disorders; pharmaceutical products and preparations for the treatment of neurodevelopmental and metabolic disorders

Goods & Services

Pharmaceutical products and preparations for the treatment of Prader-Willi syndrome (PWS) and related metabolic and neurodevelopmental disorders; pharmaceutical products and preparations for the treatment of neurodevelopmental and metabolic disorders

Goods & Services

Pharmaceutical products and preparations for the treatment of Prader-Willi syndrome (PWS) and related metabolic and neurodevelopmental disorders; pharmaceutical products and preparations for the treatment of neurodevelopmental and metabolic disorders

Abstract

The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

IPC Classes  ?

• A61K 38/095 - OxytocinsVasopressinsRelated peptides
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions

Abstract

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods. The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

IPC Classes  ?

• C07C 225/20 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Abstract

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

IPC Classes  ?

• C07D 207/16 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Abstract

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61K 38/095 - OxytocinsVasopressinsRelated peptides
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/08 - Solutions

Abstract

This disclosure provides crystalline forms of trofinetide and trofinetide hydrate, pharmaceutical compositions comprising crystalline forms of trofinetide and trofinetide hydrate, methods of making crystalline forms of trofinetide or trofinetide hydrate, and methods of treating a disease, condition, or disorder in a subject comprising administering a composition comprising crystalline forms of trofinetide or trofinetide hydrate to the subject.

IPC Classes  ?

• A01N 43/64 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/33 - Heterocyclic compounds
• A61K 38/04 - Peptides having up to 20 amino acids in a fully defined sequenceDerivatives thereof
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Methods of treating, ameliorating, and/or preventing osteoarthritic pain are provided. The methods include administering to an individual a therapeutically effective amount of a compound of Formula I (Compound 1). The method can be used to treat, ameliorate, and/or prevent osteoarthritic pain, as well as other symptoms, arising from osteoarthritis. Compound 1 can be formulated into many suitable dosage forms, including oral dosage forms such as tablets.

IPC Classes  ?

• A61K 31/426 - 1,3-Thiazoles
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

IPC Classes  ?

• C07C 225/20 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, namely, seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, chronic pain, glaucoma, Rett syndrome, autism spectrum disorders, Fragile X Syndrome (FXS), Angelman Syndrome, Tuberous Sclerosis Complex, Phelan McDermid Syndrome, CDKL5 mutations, MECP2 mutations, autism, FOXG1 Syndrome, Infantile spasm, KIF1A syndrome, Syngap1 disorder, Dravet syndrome, Mowat-Wilson syndrome, MECP2 duplication, 15q11q13 duplication, Pitt-Hopkins syndrome, Prader Willi syndrome, Ischemic injury, and Down syndrome. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders, consultation related thereto; research in the field of industrial biotechnology and biomedical research, consultation related thereto; chemical analysis, biochemical analyses, analyses in the field of molecular biology, consultation related thereto; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs, consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders, namely, seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, chronic pain, glaucoma, Rett syndrome, autism spectrum disorders, Fragile X Syndrome (FXS), Angelman Syndrome, Tuberous Sclerosis Complex, Phelan McDermid Syndrome, CDKL5 mutations, MECP2 mutations, autism, FOXG1 Syndrome, Infantile spasm, KIF1A syndrome, Syngap1 disorder, Dravet syndrome, Mowat-Wilson syndrome, MECP2 duplication, 15q11q13 duplication, Pitt-Hopkins syndrome, Prader Willi syndrome, Ischemic injury, and Down syndrome. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders, consultation related thereto; research in the field of industrial biotechnology and biomedical research, consultation related thereto; chemical analysis, biochemical analyses, analyses in the field of molecular biology, consultation related thereto; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs, consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Abstract

Disclosed herein are methods of treating Rett syndrome comprising administering trofinetide to a subject in need thereof in which a dosage is provided that may reduce or avoid underexposure, e.g., in low body weight subjects, and/or provide other benefits.

IPC Classes  ?

• A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The disclosure provides, in part, a method of treating a disorder in a patient in need of pimavanserin, the method comprising administering to the patient about 2 mg to about 80 mg of pimavanserin via, e.g., an enteral feeding tube, once daily, wherein pimavanserin is dissolved in, mixed with, or sparkled onto, e.g., about 5 mL to about 150 mL of, a liquid vehicle or soft food vehicle at ambient or cold temperature before the administration.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions

Abstract

The present disclosure relates generally to therapeutic use of pimavanserin or a pharmaceutical acceptable salt thereof. More specifically, the present disclosure provides methods for treating schizophrenia by administering pimavanserin or a pharmaceutical acceptable salt thereof as an adjunct therapy in a patient who has an inadequate response to another antipsychotic therapy.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Abstract

Behavioral pharmacological data with the compound of formula (1), a novel and selective 5HT2A/2C receptor inverse agonist, demonstrate in vivo efficacy in models of psychosis and dyskinesias. This includes activity in reversing MK-801 induced locomotor behaviors, suggesting that this compound may be an efficacious anti-psychotic, and activity in an MPTP primate model of dyskinesias, suggesting efficacy as an anti-dyskinesia agent. These data support the hypothesis that SHT2A/2C receptor inverse agonism may confer antipsychotic and anti-dyskinetic efficacy in humans, and indicate a use of the compound of formula (I) and related agents as novel therapeutics for Parkinson's Disease, related human neurodegenerative diseases, and psychosis.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07D 211/58 - Nitrogen atoms attached in position 4
• A61K 31/194 - Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
• C07C 59/255 - Tartaric acid
• A61K 9/20 - Pills, lozenges or tablets

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs (term considered too vague by the International Bureau - Rule 13 (2) (b) of the Regulations); consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders.

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders. Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto.

Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

IPC Classes  ?

• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/20 - Pills, lozenges or tablets
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

This disclosure provides, in part, a method of treating major depression, psychosis secondary to neurodegenerative disorders, or schizophrenia in a patient in need thereof, wherein the patient is currently taking a daily dose of an SSRI or an SNRI that prolongs the QT interval, comprising administering a daily dose of pimavanserin to the patient and continuing administering the SSRI or the SNRI, and wherein upon the administration of the pimavanserin, the QT interval of the patient does not significantly increase.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Abstract

The present invention is directed to novel neuro-attenuating norketamine (NANKET) compounds according to any one of formulas (I—shown below), (I-A) and (I-B), or any of the compounds described in Tables A-D, or in any of the Examples provided herein, and pharmaceutically acceptable salts thereof, novel pharmaceutical formulations and novel methods of uses thereof. The present invention also features novel oral neuro-attenuating ketamine (NAKET) and neuro-attenuating norketamine (NANKET) modified-release pharmaceutical formulations, and novel methods of administration thereof, which ensure the steady release of a therapeutically effective amount of ketamine, norketamine, or derivatives thereof from the oral modified-release pharmaceutical formulations without neurologically toxic spikes in plasma concentration of the ketamine, norketamine, or derivatives during the release periods.

IPC Classes  ?

• C07C 225/20 - Compounds containing amino groups and doubly-bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly-bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone

Abstract

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Prader-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61K 38/095 - OxytocinsVasopressinsRelated peptides
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/08 - Solutions

Goods & Services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders namely seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; research in the field of industrial biotechnology and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related to medical testing, namely, in vitro and in vivo preclinical testing of potential drugs.

Goods & Services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders namely seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; research in the field of industrial biotechnology and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related to medical testing, namely, in vitro and in vivo preclinical testing of potential drugs.

Goods & Services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders namely seizure disorders, mood disorders, anxiety disorders, cognitive disorders, schizophrenia, psychoses, bipolar disorders, eating disorders, gambling addictions, drug addictions, internet addictions, Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma. (1) Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical referrals. (2) Scientific research in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; research in the field of industrial biotechnology and biomedical research; chemical, biochemical and molecular biological analyses; providing medical and scientific research information in the field of pharmaceuticals and clinical trials. (3) Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders to health care providers, caregivers, and patients; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related to medical testing, namely, in vitro and in vivo preclinical testing of potential drugs.

Abstract

2 or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

IPC Classes  ?

• C07D 211/58 - Nitrogen atoms attached in position 4
• C07D 211/98 - Nitrogen atom

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs and consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs; and consultation related to all the foregoing services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs; and consultation related to all the foregoing services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs; and consultation related to all the foregoing services; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, genetic, psychologic, and psychiatric diseases and disorders Promoting awareness of patient support offerings for neurologic, genetic, psychologic, and psychiatric diseases and disorders; business administrative services for medical referrals Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing in the nature of pharmaceutical testing, namely, in vitro and in vivo preclinical testing of potential drugs and consultation related thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials Medical consulting with respect to neurologic, genetic, psychologic, and psychiatric diseases and disorders, including Rett syndrome and its identification and treatment; providing online information for health care providers, caregivers, and patients in the field of neurologic, genetic, psychologic, and psychiatric diseases and disorders; medical informational support services, namely, providing information about the benefits of diagnostic tools, medical information regarding disease diagnosis, identification, treatment, and management, and healthcare-related information to patients, caregivers, and healthcare professionals all related to neurologic, genetic, psychologic, and psychiatric diseases and disorders

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders. Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; in vitro and in vivo preclinical testing of potential drugs; consultation related thereto. Medical testing.

Abstract

Disclosed herein are methods of treating Rett syndrome comprising administering trofinetide to a subject in need thereof in which a dosage is provided that may reduce or avoid underexposure, e.g., in low body weight subjects, and/or provide other benefits.

IPC Classes  ?

• A61K 38/06 - Tripeptides
• A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
• C07K 5/08 - Tripeptides
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

The present disclosure relates to compounds according to Formulae (I), (II) and (VIII), useful for treating diseases.

IPC Classes  ?

• C07D 211/58 - Nitrogen atoms attached in position 4
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems

Abstract

The disclosure provides, in part, a method of treating a disorder in a patient in need of pimavanserin, the method comprising administering to the patient about 2 mg to about 80 mg of pimavanserin via, e.g., an enteral feeding tube, once daily, wherein pimavanserin is dissolved in, mixed with, or sparkled onto, e.g., about 5 mL to about 150 mL of, a liquid vehicle or soft food vehicle at ambient or cold temperature before the administration.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present disclosure relates generally to therapeutic use of pimavanserin or a pharmaceutical acceptable salt thereof. More specifically, the present disclosure provides methods for treating schizophrenia by administering pimavanserin or a pharmaceutical acceptable salt thereof as an adjunct therapy in a patient who has an inadequate response to another antipsychotic therapy.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl

Goods & Services

(1) Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders, namely Parkinson's disease, Alzheimer's disease, schizophrenia, chronic pain and glaucoma (1) Scientific research in the field of neurologic, metabolic and genetic diseases and disorders; industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; in vitro and in vivo preclinical testing of potential drugs; medical consulting with respect to neurologic, metabolic, and genetic conditions and their treatment

Abstract

The application describes stable aqueous compositions comprising relatively high concentrations of carbetocin and a solubilizer and/or surface active agent. The disclosed carbetocin compositions are effective in the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin compositions show improved stability at room temperature and/or under accelerated conditions of stress.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• C07K 7/64 - Cyclic peptides containing only normal peptide links
• A61K 38/095 - OxytocinsVasopressinsRelated peptides
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions

Abstract

Provided herein are methods of making a thiazoline anti-hyperalgesic, Compound 1, and polymorphs thereof. The methods described herein use inexpensive reagents and are capable of providing Compound 1 in commercial-scale quantities. Also provided are pharmaceutical compositions of Compound 1 suitable for human administration.

IPC Classes  ?

• C07D 277/18 - Nitrogen atoms

Goods & Services

Downloadable electronic publications in the nature of brochures, pamphlets, reports, newsletters, articles, guidebooks, case studies and white papers in the field of neurologic, metabolic, and genetic diseases and disorders, patient support, and medical information regarding disease management Publications in the nature of brochures, pamphlets, newsletters, articles and guidebooks in the field of neurologic, metabolic, and genetic diseases and disorders, patient support, and medical information regarding disease management Promoting awareness of patient support offerings for neurodegenerative diseases and disorders and dementia; Business administrative services for medical referrals Educational services, namely, providing educational programs about neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions; multimedia educational services in the nature of recording and production services in the fields of neurologic, metabolic, and genetic diseases and disorders, medical informational support services, and medical information regarding disease management; providing on-line newsletters in the field of neurologic, metabolic, and genetic diseases and disorders, medical informational support services, and medical information regarding disease management; providing online non-downloadable electronic publications in the nature of brochures, pamphlets, reports, newsletters, articles, guidebooks, case studies and white papers in the field of neurologic, metabolic, and genetic diseases and disorders, patient support, and medical information regarding disease management Medical consulting with respect to neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical informational support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals all related to neurologic, metabolic and genetic diseases and disorders

Abstract

The present disclosure relates to compounds according to Formula (I), useful for treating diseases.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 211/58 - Nitrogen atoms attached in position 4
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.

IPC Classes  ?

• A61K 9/20 - Pills, lozenges or tablets
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/13 - Amines, e.g. amantadine

Abstract

Methods for the treatment of Alzheimer's disease psychosis, or a symptom thereof, comprising administering pimavanserin. Also provided herein are methods for the treatment of delusions and/or hallucinations in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing NPI-NH score in a human with Alzheimer's Disease comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof. Also provided herein are methods for reducing agitated behavior or aggressive behavior in a human with dementia comprising administering pimavanserin, or a pharmaceutically acceptable salt thereof.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/27 - Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, e.g. meprobamate, carbachol, neostigmine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/473 - QuinolinesIsoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
• A61K 31/549 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto

Goods & Services

Pharmaceuticals for use in the prevention and treatment of neurologic, metabolic, genetic, psychologic and psychiatric diseases and disorders Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto

Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/38 - CelluloseDerivatives thereof

Goods & Services

Scientific and industrial biotechnological and biomedical research; chemical, biochemical and molecular biological analyses; medical testing, namely, in vitro and in vivo preclinical testing of potential drugs; consultation related thereto

Abstract

2 or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

IPC Classes  ?

• C07D 211/58 - Nitrogen atoms attached in position 4

Abstract

2 or F; Also disclosed herein is the tartrate salt of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) carbamide and methods for obtaining the salt.

IPC Classes  ?

• C07D 211/58 - Nitrogen atoms attached in position 4

Goods & Services

Printed publications in the nature of brochures, pamphlets, newsletters, written articles and guidebooks in the field of medical information and patient support Promoting awareness of patient support offerings for neurologic, metabolic, rare, and genetic diseases and disorders; promoting awareness of patient support offerings for pain associated with neurologic, metabolic, rare, and genetic diseases and disorders; business administration of reimbursement and medical benefit information for neurologic, metabolic, rare, and genetic conditions and their treatment; business administration of reimbursement and medical benefit information for treatment of pain associated with neurologic, metabolic, rare, and genetic conditions; Business administrative services for medical referrals Providing a website featuring financial information regarding medical benefits and reimbursements available for medical expenses related thereto; insurance services, namely, benefits verification in the nature of insurance claims administration; providing online information and financial assistance with insurance benefits and coverage for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders Educational services, namely, conducting educational programs in the fields of neurologic, metabolic, and genetic diseases and disorders and treatment and patient support options for these conditions Medical consulting in the fields of neurologic, metabolic, and genetic conditions and their treatment; providing online information for health care providers and patients in the field of neurologic, metabolic and genetic diseases and disorders; medical support services, namely, providing information about the therapeutic benefits of pharmaceutical products, medical information regarding disease management, and healthcare-related information to patients and healthcare professionals in the fields of neurologic, metabolic and genetic diseases and disorders

Abstract

NNNNNNN'-(4-(2- methylpropyloxy)phenylmethyl)carbamide once daily, as well as methods for the treatment of a SSRI or SNRI- induced sexual dysfunction in a human subject.

IPC Classes  ?

• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/15 - Oximes (C=N—O—)Hydrazines (N—N)Hydrazones (N—N=)
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/4525 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/24 - Antidepressants
• A61P 25/22 - Anxiolytics
• A61P 15/10 - Drugs for genital or sexual disordersContraceptives for impotence

Goods & Services

Providing on-line non-downloadable software for administering medical benefit and enrolling in benefits patient support program services

Abstract

The present disclosure includes a method of making an improved carbetocin drug product. The disclosed method for making an improved carbetocin drug product comprises agitating a carbetocin preparation containing an aqueous solution of carbetocin and one or more excipients for a period of time to initiate the formation of aggregate-forming solids and filtering off the aggregates that form before further processing the remaining carbetocin into a final drug product. The present disclosure also relates to an improved carbetocin drug product, wherein the drug product is substantially free of aggregate-forming solids. The disclosed carbetocin drug product can be used for the treatment of a neurodevelopmental disorder, such as Präder-Willi syndrome. Additionally, the disclosed carbetocin drug product shows content uniformity of carbetocin over long periods of time before and after one or more freeze/thaw cycles, provides enhanced convenience and patient compliance, and/or are highly concentrated.

IPC Classes  ?

• A61K 38/12 - Cyclic peptides
• A61K 38/095 - OxytocinsVasopressinsRelated peptides
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 9/08 - Solutions

Abstract

A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/16 - Anti-Parkinson drugs

Abstract

A method for treating a impulse control disorder in a patient comprising administering to the patient an effective amount of pimavanserin or a pharmaceutical acceptable salt thereof.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid

Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The invention relates to compounds of formula (I), compositions containing the same, and methods for treating and/or diminishing pain in a subject in need thereof. The compounds of formula (I) are effective for treating opioid-induced tachyphylaxis and opioid-induced hyperalgesia.

IPC Classes  ?

• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 25/04 - Centrally acting analgesics, e.g. opioids

Abstract

Provided herein are methods for assessing a patient's suicidality. Also provided herein are methods for including or excluding a patient from a clinical study group.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment

Abstract

A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61K 9/20 - Pills, lozenges or tablets
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for treating a disease or disorder in a patient who is currently taking a cytochrome P450 inhibitor comprising administering to the patient a dose of pimavanserin or a pharmaceutical acceptable salt thereof, wherein the dose is at least 20% lower than a dose of pimavanserin or a pharmaceutical acceptable salt thereof that would otherwise have been recommended to the patient if the patient were not currently taking the cytochrome P450 inhibitor.

IPC Classes  ?

• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 25/18 - Antipsychotics, i.e. neurolepticsDrugs for mania or schizophrenia
• A61P 25/24 - Antidepressants
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

Provided herein are capsules containing pimavanserin, processes for manufacturing said capsule, and pharmaceutical compositions containing pimavanserin.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
• A61K 31/4468 - Non-condensed piperidines, e.g. piperocaine having a nitrogen atom directly attached in position 4, e.g. clebopride, fentanyl